https://www.selleckchem.com/products/wz-811.html
Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a m
Like
Comment
Share
